Beta-lactam resistant Pseudomonas aeruginosa strains emerging during therapy: synergistic resistance mechanisms. 1988

L Pagani, and M Debiaggi, and R Tenni, and P M Cereda, and P Landini, and E Romero
Institute of Microbiology, University of Pavia, Italy.

The emergence of beta-lactam resistant strains of Pseudomonas aeruginosa during treatment was studied. Three different strains present before treatment persisted with changes in their beta-lactam resistance during treatment. The isolates before and after therapy were studied for beta-lactamase production and permeability barrier. The increased beta-lactam resistance was correlated with an increased permeability barrier. In order to verify if the permeability barrier was correlated with changes in outer membrane proteins, outer membrane preparations were analyzed by SDS-PAGE. Several differences were observed between the OMP profiles of the post therapy and the pre therapy isolates. Furthermore, an analysis of PBPs pattern of strains studied was carried out and alterations in target proteins were observed.

UI MeSH Term Description Entries
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D010458 Peptidyl Transferases Acyltransferases that use AMINO ACYL TRNA as the amino acid donor in formation of a peptide bond. There are ribosomal and non-ribosomal peptidyltransferases. Peptidyl Transferase,Peptidyl Translocase,Peptidyl Translocases,Peptidyltransferase,Transpeptidase,Transpeptidases,Peptidyltransferases,Transferase, Peptidyl,Transferases, Peptidyl,Translocase, Peptidyl,Translocases, Peptidyl
D010957 Plasmids Extrachromosomal, usually CIRCULAR DNA molecules that are self-replicating and transferable from one organism to another. They are found in a variety of bacterial, archaeal, fungal, algal, and plant species. They are used in GENETIC ENGINEERING as CLONING VECTORS. Episomes,Episome,Plasmid
D011550 Pseudomonas aeruginosa A species of gram-negative, aerobic, rod-shaped bacteria commonly isolated from clinical specimens (wound, burn, and urinary tract infections). It is also found widely distributed in soil and water. P. aeruginosa is a major agent of nosocomial infection. Bacillus aeruginosus,Bacillus pyocyaneus,Bacterium aeruginosum,Bacterium pyocyaneum,Micrococcus pyocyaneus,Pseudomonas polycolor,Pseudomonas pyocyanea
D011552 Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS. Infections, Pseudomonas,Pseudomonas aeruginosa Infection,Infection, Pseudomonas,Pseudomonas Infection,Pseudomonas aeruginosa Infections
D002267 Muramoylpentapeptide Carboxypeptidase Enzyme which catalyzes the peptide cross-linking of nascent CELL WALL; PEPTIDOGLYCAN. Carboxypeptidase Transpeptidase,Carboxypeptidase, Muramoylpentapeptide,Transpeptidase, Carboxypeptidase
D002352 Carrier Proteins Proteins that bind or transport specific substances in the blood, within the cell, or across cell membranes. Binding Proteins,Carrier Protein,Transport Protein,Transport Proteins,Binding Protein,Protein, Carrier,Proteins, Carrier
D002463 Cell Membrane Permeability A quality of cell membranes which permits the passage of solvents and solutes into and out of cells. Permeability, Cell Membrane
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D006602 Hexosyltransferases Enzymes that catalyze the transfer of hexose groups. EC 2.4.1.-.

Related Publications

L Pagani, and M Debiaggi, and R Tenni, and P M Cereda, and P Landini, and E Romero
July 2012, Mikrobiyoloji bulteni,
L Pagani, and M Debiaggi, and R Tenni, and P M Cereda, and P Landini, and E Romero
November 2005, Antimicrobial agents and chemotherapy,
L Pagani, and M Debiaggi, and R Tenni, and P M Cereda, and P Landini, and E Romero
May 1981, Antimicrobial agents and chemotherapy,
L Pagani, and M Debiaggi, and R Tenni, and P M Cereda, and P Landini, and E Romero
June 1984, Journal of medical microbiology,
L Pagani, and M Debiaggi, and R Tenni, and P M Cereda, and P Landini, and E Romero
December 1988, The Journal of antimicrobial chemotherapy,
L Pagani, and M Debiaggi, and R Tenni, and P M Cereda, and P Landini, and E Romero
June 1982, Lancet (London, England),
L Pagani, and M Debiaggi, and R Tenni, and P M Cereda, and P Landini, and E Romero
April 1987, The Journal of antimicrobial chemotherapy,
L Pagani, and M Debiaggi, and R Tenni, and P M Cereda, and P Landini, and E Romero
February 1987, European journal of clinical microbiology,
L Pagani, and M Debiaggi, and R Tenni, and P M Cereda, and P Landini, and E Romero
May 2011, Antimicrobial agents and chemotherapy,
L Pagani, and M Debiaggi, and R Tenni, and P M Cereda, and P Landini, and E Romero
January 2013, Current pharmaceutical design,
Copied contents to your clipboard!